The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection

Virol J. 2023 Oct 3;20(1):222. doi: 10.1186/s12985-023-02183-z.

Abstract

Viral infections in humans are responsible for fatalities worldwide and contribute to the incidence of various human ailments. Controllable targeted medicine delivery against many illnesses, including viral infection, may be significantly aided by using bacteria and bacteria-derived products. They may accumulate in diseased tissues despite physical obstacles, where they can launch antiviral immunity. The ability to genetically and chemically modify them means that vaccinations against viral infections may be manufactured and delivered to affected tissues more safely and effectively. The objective of this study is to provide an overview of the latest advancements in the field of utilizing bacteria and bacterial derivatives as carriers for administering medication to treat viral diseases such as SARS-CoV-2, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human papillomavirus, influenza, and Ebola virus.

Keywords: Bacteria; Bacterial derivatives; Drug delivery system; Vaccine; Viral infection.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Bacteria
  • COVID-19*
  • Drug Delivery Systems
  • Humans
  • SARS-CoV-2
  • Virus Diseases* / drug therapy

Substances

  • Antiviral Agents